Please login to the form below

Not currently logged in
Email:
Password:

Baxter reveals collaboration for next-generation home haemodialysis

Baxter collaborates with DEKA Research & Development and HHD for the development of a next-generation home haemodialysis machine

Baxter International has collaborated with DEKA Research & Development and HHD for the development of a next-generation home haemodialysis machine.

Baxter and DEKA have collaborated on other successful products in the past, most notably on the design and development of Baxter's HomeChoice automated peritoneal dialysis machine.

Per the collaboration agreement, Baxter has purchased an option to acquire the assets of HHD and will fund DEKA's related R&D activities. Baxter may also make future royalty payments to DEKA. Baxter expects to record a special net pre-tax charge of up to USD 25m (USD 0.04 per diluted share) for in-process R&D associated with this transaction in Q3 2007.

Bruce McGillivray, president of Baxter's renal business, said: "This collaboration highlights Baxter's ongoing commitment to innovation in end-stage renal disease (ESRD) treatment. Our global leadership in home dialysis therapy, combined with DEKA's new medical product development expertise, will allow us to advance this promising technology at a faster pace."

7th August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics